| Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 20651319 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
PURPOSE: Differences in dosing patterns and costs among patients with rheumatoid arthritis (RA) treated with the tumor necrosis factor (TNF) inhibitors etanercept, adalimumab, and infliximab were analyzed on the basis of claims data. METHODS: Commercial health insurance claims data from January 2004 through December 2005 from the PharMetrics Patient-centric Database were analyzed. Adults (> or =18 years of age) with RA with a minimum of two claims for the same TNF inhibitor within a 12-month period and with at least 18 months of continuous enrollment in the database (encompassing a 6-month preindex period and a 12-month follow-up period) were included. Patients were considered treatment naive if they had no claims for a TNF inhibitor during the preindex period; continuing patients had at least one TNF-inhibitor claim during the preindex period. RESULTS: A total of 845 treatment-naive and 3783 continuing patients were included. Medication use, costs, and health care use were generally similar among the treatment groups in the preindex period for both naive and continuing patients. Among both naive and continuing patients, dose increases from the first to the last prescription were most likely to occur in the infliximab group (26% and 24%, respectively) compared with the adalimumab (10% and 9%) and etanercept (1% and 3%) groups. Etanercept was associated with the lowest and infliximab with the highest total anti-TNF therapy costs. Anti-TNF-related costs were higher among patients with a high index dose, a dose increase, or both during the follow-up period than among those without. CONCLUSION: Dose increases with TNF inhibitors commonly occurred in RA patients in the clinical setting and were associated with greater costs of anti-TNF therapy. |
| | |
Authors:
|
David J Harrison; Xingyue Huang; Denise Globe |
Related Documents
:
|
3885439 - A clinical evaluation of isoxicam in the treatment of osteo-arthritis. 3474779 - An open study on the efficacy and safety of auranofin in treating psoriatic arthritis. 23015369 - Balloon aortic valvuloplasty for severe aortic stenosis as a bridge to transcatheter/su... 23240859 - The effect of a preoperative erythropoietin protocol as part of a multifaceted blood ma... 17382609 - Treatment of life-threatening type i refractory coeliac disease with long-term infliximab. 23636409 - Intraventricular fibrinolysis for severe aneurysmal intraventricular hemorrhage: a rand... 8291729 - The effect of epidural versus general anesthesia on postoperative pain and analgesic re... 19707769 - Ct colonography with minimal bowel preparation: evaluation of tagging quality, patient ... 21915769 - Surgical technique: a cup-in-cup technique to restore offset in severe protrusio acetab... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Volume: 67 ISSN: 1535-2900 ISO Abbreviation: Am J Health Syst Pharm Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-23 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9503023 Medline TA: Am J Health Syst Pharm Country: United States |
Other Details:
|
Languages: eng Pagination: 1281-7 Citation Subset: IM |
Affiliation:
|
Global Health Economics; Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA. davidh01@amgen.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Influence of medications and diagnoses on fall risk in psychiatric inpatients.
Next Document: Speaking for the evidence: colonoscopy vs computed tomographic colonography.